Efficient dual treatment of the hormone-refractory prostate cancer cell line DU145 with cetuximab and 1,25-dihydroxyvitamin D3

Olga Belochitski, Samuel Ariad, Shraga Shany, Vladimir Fridman, Vladimir Gavrilov

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background: Targeting of the epidermal growth factor receptor (EGFR) pathway is a promising treatment strategy for aggressive androgen-refractory prostate cancer (PCa). The effect of treating the androgen-resistant PCa cell line DU145 with a combination of the anti-EGFR drug cetuximab and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) was evaluated. Materials and methods: DU145 cells were treated with 5 nM cetuximab, 100 nM 1,25(OH)2D3 or a combination of both. The effect of the treatments on cell growth, cell-cycle and apoptosis was evaluated. Results: Single-drug treatments decreased DU145 cell growth by up to 25% and caused a 1.5- to 1.7-fold increase of apoptosis, but did not affect the cell-cycle distribution. However, dual treatment with a combination of cetuximab and 1,25(OH)2D3 inhibited DU145 cell proliferation by 40%, caused considerable cell-cycle arrest in the G0/G1-phase, and enhanced apoptosis by 2.5-fold (compared to the control, p<0.0001, p<0.006 and p<0.0001, respectively). Conclusion: A combination of cetuximab and 1,25(OH)2D3 efficiently suppresses hormone-resistant PCa cell growth and could provide a basis for its clinical application.

Original languageEnglish
Pages (from-to)371-376
Number of pages6
JournalIn Vivo
Volume21
Issue number2
StatePublished - 1 Jan 2007

Keywords

  • 1,25-dihydroxyvitamin D
  • Cetuximab
  • DU145
  • EGF
  • EGFR
  • Hormone-refractory prostate cancer
  • Vitamin D
  • anti-EGFR antibody

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology (all)
  • Pharmacology

Fingerprint

Dive into the research topics of 'Efficient dual treatment of the hormone-refractory prostate cancer cell line DU145 with cetuximab and 1,25-dihydroxyvitamin D3'. Together they form a unique fingerprint.

Cite this